Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

EU mid-market update: Trump adds Middle East tensions to macro picture as trade war keeps volatility high; Novo Nordisk rises ...

Germany's service activity growth hits six-month high. France (CAC:IND) -0.27% France service activity falls in January. Industrial production fell 0.4% M/M in December. Iceland’s Central Bank cut its ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

The president has recently hit out the EU, accusing the 27-member bloc of having "taken advantage" of the U.S. through a ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

Commenting on the Champions Initiative, Cradle co-founder and chief executive Stef van Grieken said that technological ...

The higher he climbs, the less he thinks about daily life, says Novo Nordisk’s Cem Ozenc. There’s no time when the mental and ...